Insmed Share Price (NASDAQ: INSM)

$135.51

▲

0.54

(0.4%)

Live

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Insmed Stock chart to analyse performance

Insmed stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$134.57
Today's High:$135.54
$135.51
0.69%
Downside
Day's Volatility :0.72%
Upside
0.02%
52 Weeks Low:$60.40
52 Weeks High:$136.71
$135.51
55.43%
Downside
52 Weeks Volatility :55.82%
Upside
0.88%

Insmed Stock Returns

Period	Insmed Incorporated	Sector (Health Care)	Index (Russel 2000)
3 Months	93.95%	3.1%	0.0%
6 Months	65.84%	-8.4%	0.0%
1 Year	77.18%	-12.6%	0.0%
3 Years	466.09%	7.9%	-6.1%

Insmed Incorporated Key Stats

Check Insmed key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$134.97
Open	$135.5
Today's High	$136.07
Today's Low	$134.57
Market Capitalization	$28.5B
Today's Volume	$1.8M
52 Week High	$136.71
52 Week Low	$60.4
Revenue TTM	$398.1M
EBITDA	$-917.5M
Earnings Per Share (EPS)	$-5.66
Profit Margin	-259.82%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-160.54%

Stock Returns calculator for Insmed Stock including INR - Dollar returns

The Insmed stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Insmed investment value today

Current value as on today

₹1,82,851

Returns

₹82,851

(+82.85%)

Returns from Insmed Stock

₹77,532 (+77.53%)

Dollar Returns*

₹5,319 (+5.32%)

Indian investors sentiment towards Insmed Stock

129.17%

Period: Jul 29, 2025 to Aug 28, 2025. Change in 30 Days versus previous period

Investment in Insmed Shares from India has grown by 129.17% over the past 30 days, indicating increased transactional activity.

140%

Period: Jul 29, 2025 to Aug 28, 2025. Change in 30 Days versus previous period

Search interest for Insmed Stock from India on INDmoney has increased by 140% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Insmed Incorporated

Name
Holdings %
Name
Holdings %
Vanguard Group Inc
8.36%
BlackRock Inc
7.60%
Darwin Global Management, Ltd.
7.29%
T. Rowe Price Associates, Inc.
5.32%
Baker Bros Advisors LP
3.65%
Capital Research & Mgmt Co - Division 3
3.54%

Analyst Recommendation on Insmed Stock

Rating

Trend

Buy

95%Buy

4%Hold

0%Sell

Based on 23 Wall street analysts offering stock ratings for Insmed(by analysts ranked 0 to 5 stars)

Insmed Share Price Target

What analysts predicted

Upside of 9.54%

Target:

$148.44

Current:

$135.51

Insmed share price target is $148.44, a slight Upside of 9.54% compared to current price of $135.51 as per analysts' prediction.

Insmed Stock Insights

Price Movement
In the last 1 month, INSM stock has moved up by 28.8%
Increasing Revenue
Insmed Incorporated has shown positive revenue growth over the last two quarters. Revenue increased from $92.82 million to $107.41 million, resulting in an average quarterly increase of 13.6%.
Decreasing Net Profit
Insmed Incorporated has seen a decline in its net profit over the last four quarters. The net profit decreased from -220.52 million dollars to -321.68 million dollars. This change reflects an average decrease of 13.7% in net profit each quarter.

Insmed Incorporated Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$136.5M	↑ 1287.56%
Net Income	$-254.3M	↓ 21.57%
Net Profit Margin	-186.37%	↑ 3110.8%

	FY20	Y/Y Change
Revenue	$164.4M	↑ 20.48%
Net Income	$-294.1M	↑ 15.63%
Net Profit Margin	-178.87%	↑ 7.5%

	FY21	Y/Y Change
Revenue	$188.5M	↑ 14.63%
Net Income	$-434.7M	↑ 47.8%
Net Profit Margin	-230.63%	↓ 51.76%

	FY22	Y/Y Change
Revenue	$245.4M	↑ 30.19%
Net Income	$-481.5M	↑ 10.79%
Net Profit Margin	-196.26%	↑ 34.37%

	FY23	Y/Y Change
Revenue	$305.2M	↑ 24.39%
Net Income	$-749.6M	↑ 55.66%
Net Profit Margin	-245.59%	↓ 49.33%

	FY24	Y/Y Change
Revenue	$363.7M	↑ 19.17%
Net Income	$-913.8M	↑ 21.91%
Net Profit Margin	-251.24%	↓ 5.65%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$75.5M	↓ 9.79%
Net Income	$-157.1M	↓ 15.57%
Net Profit Margin	-208.07%	↑ 14.24%

	Q2 FY24	Q/Q Change
Revenue	$90.3M	↑ 19.66%
Net Income	$-300.6M	↑ 91.36%
Net Profit Margin	-332.75%	↓ 124.68%

	Q3 FY24	Q/Q Change
Revenue	$93.4M	↑ 3.41%
Net Income	$-220.5M	↓ 26.64%
Net Profit Margin	-236.04%	↑ 96.71%

	Q4 FY24	Q/Q Change
Revenue	$104.4M	↑ 11.79%
Net Income	$-235.5M	↑ 6.81%
Net Profit Margin	-225.53%	↑ 10.51%

	Q1 FY25	Q/Q Change
Revenue	$92.8M	↓ 11.12%
Net Income	$-256.6M	↑ 8.93%
Net Profit Margin	-276.42%	↓ 50.89%

	Q2 FY25	Q/Q Change
Revenue	$107.4M	↑ 15.72%
Net Income	$-321.7M	↑ 25.37%
Net Profit Margin	-299.48%	↓ 23.06%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$112.3M	↑ 1414.5%

	FY20	Y/Y Change
Profit	$124.5M	↑ 10.94%

	FY21	Y/Y Change
Profit	$144.3M	↑ 15.87%

	FY22	Y/Y Change
Profit	$190.2M	↑ 31.82%

	FY23	Y/Y Change
Profit	$239.6M	↑ 25.97%

	FY24	Y/Y Change
Profit	$278.0M	↑ 16.0%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$56.8M	↓ 12.98%

	Q2 FY24	Q/Q Change
Profit	$68.1M	↑ 19.96%

	Q3 FY24	Q/Q Change
Profit	$72.3M	↑ 6.08%

	Q4 FY24	Q/Q Change
Profit	$78.3M	↑ 8.35%

	Q1 FY25	Q/Q Change
Profit	$71.5M	↓ 8.62%

	Q2 FY25	Q/Q Change
Profit	$78.1M	↑ 9.13%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-250.6M	↓ 2.84%
Investing Cash Flow	$-42.3M	↑ 185.32%
Financing Cash Flow	$285.3M	↓ 26.24%

	FY20	Y/Y Change
Operating Cash Flow	$-219.3M	↓ 12.49%
Investing Cash Flow	$-6.8M	↓ 83.86%
Financing Cash Flow	$271.0M	↓ 5.0%

	FY21	Y/Y Change
Operating Cash Flow	$-363.3M	↑ 65.63%
Investing Cash Flow	$-64.3M	↑ 842.32%
Financing Cash Flow	$612.5M	↑ 126.03%

	FY22	Y/Y Change
Operating Cash Flow	$-400.4M	↑ 10.22%
Investing Cash Flow	$-34.6M	↓ 46.2%
Financing Cash Flow	$793.3M	↑ 29.5%

	FY23	Y/Y Change
Operating Cash Flow	$-536.2M	↑ 33.91%
Investing Cash Flow	$-223.6M	↑ 546.55%
Financing Cash Flow	$168.4M	↓ 78.77%

	FY24	Y/Y Change
Operating Cash Flow	$-683.9M	↑ 27.53%
Investing Cash Flow	$-583.2M	↑ 160.81%
Financing Cash Flow	$1.3B	↑ 696.15%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-184.0M	↑ 40.68%
Investing Cash Flow	$295.3M	↑ 16279.42%
Financing Cash Flow	$3.0M	↓ 97.55%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-123.0M	↓ 33.19%
Investing Cash Flow	$-6.8M	↓ 102.3%
Financing Cash Flow	$781.5M	↑ 25760.13%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-180.9M	↑ 47.14%
Investing Cash Flow	$-1.0B	↑ 14693.91%
Financing Cash Flow	$397.2M	↓ 49.17%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-196.0M	↑ 8.33%
Investing Cash Flow	$131.8M	↓ 113.13%
Financing Cash Flow	$159.3M	↓ 59.89%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-262.1M	↑ 33.73%
Investing Cash Flow	$80.4M	↓ 38.97%
Financing Cash Flow	$29.0M	↓ 81.8%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-205.6M	↓ 21.56%
Investing Cash Flow	$227.8M	↑ 183.33%
Financing Cash Flow	$857.8M	↑ 2858.16%

Insmed Technicals Summary

Sell

Neutral

Buy

Insmed is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Insmed Incorporated Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Insmed Incorporated	28.58%	65.84%	77.18%	466.09%	379.74%
Regeneron Pharmaceuticals, Inc.	3.77%	-17.64%	-51.18%	-2.19%	-7.17%
Beone Medicines Ltd	-0.02%	10.33%	51.07%	81.16%	24.14%
Vertex Pharmaceuticals Incorporated	-16.39%	-18.24%	-20.49%	39.42%	40.54%
Alnylam Pharmaceuticals, Inc.	33.05%	83.22%	57.52%	115.32%	240.85%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Insmed Incorporated	NA	NA	0.0	-5.51	-1.61	-0.27	NA	5.92
Regeneron Pharmaceuticals, Inc.	14.79	14.79	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.69	27.69	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Insmed Incorporated	Buy	$28.5B	379.74%	NA	-259.82%
Regeneron Pharmaceuticals, Inc.	Buy	$62.2B	-7.17%	14.79	31.37%
Beone Medicines Ltd	NA	$36.8B	24.14%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$99.8B	40.54%	27.69	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.1B	240.85%	NA	-12.96%

Insmed Dividend announcements

Insmed Earnings
Insmed’s price-to-earnings ratio stands at None

About Insmed Incorporated

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops gene therapy, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as is in pre-clinical development for gene therapy, next generation DPP1 inhibitor, deimmunized therapeutic protein, and synthetic rescue. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Organization	Insmed
Employees	1271
CEO	Mr. William H. Lewis J.D., M.B.A.
Industry	Health Technology

Key Management of Insmed Incorporated

Name	Title
Mr. William H. Lewis J.D., M.B.A.	President, CEO & Chairman
Ms. Sara M. Bonstein M.B.A.	Chief Financial Officer
Mr. Roger Adsett M.B.A.	Chief Operating Officer
Mr. John Drayton Wise M.B.A.	Consultant
Dr. Martina Flammer M.B.A., M.D.	Chief Medical Officer
Mr. Brian K. Kaspar Ph.D.	Chief Scientific Officer
Bryan Dunn	Vice President of Investor Relations
Mr. Michael Alexander Smith J.D.	Chief Legal Officer & Corporate Secretary
Ms. Claire Mulhearn	Vice President of Corporate Communications
Ms. S. Nicole Schaeffer M.B.A.	Chief People Strategy Officer

Important FAQs about investing in INSM Stock from India :

What is Insmed share price today?

Insmed share price today is $135.51 as on August 30, 2025 at 1:29 am IST. Insmed share today touched a day high of $135.54 and a low of $134.57.

What is the 52 week high and 52 week low for Insmed share?

Insmed share touched a 52 week high of $136.71 and a 52 week low of $60.40. Insmed stock price today i.e. August 30, 2025 at 1:29 am IST is trending at $135.51, lower by 0.88% versus the 52 week high.

How to invest in Insmed Stock (INSM) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Insmed on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Insmed Shares that will get you 0.0111 shares as per Insmed share price of $135.51 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Insmed Stock (INSM) from India?

Indian investors can start investing in Insmed (INSM) shares with as little as ₹88.286 or $1 (as of August 29, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Insmed stock (as per the Rupee-Dollar exchange rate as on August 29, 2025). Based on Insmed share’s latest price of $135.51 as on August 30, 2025 at 1:29 am IST, you will get 0.0738 shares of Insmed. Learn more about fractional shares .

What are the returns that Insmed has given to Indian investors in the last 5 years?

Insmed stock has given 379.74% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?